Development of a clinical hemoglobin modulator

Ended Project Grant Awarded Last action

Award ID
R33HL147845
Recipient
Awarding agency
Obligated
$12,368,252

Award facts

Assistance listing
93.837 Cardiovascular Diseases Research
Completion date
Originally
Funding
  • $10,524,443.00 Federal
  • $1,843,809.00 Non-federal
Place of performance
Weston, MA 02493, USA

Award details come from USAspending.gov.

Transactions

Action Federal Non-federal Date
Amendment Development of a clinical hemoglobin modulator - the β-thalassemias and hemoglobinopathies are serious genetic blood diseases, which are who-designated as a… $0 $0
Amendment $1,630,002 $0
Amendment $1,630,002 $0
Amendment $1,843,809 $0
Amendment $1,843,809 $0
Amendment Development of a clinical hemoglobin modulator - the SS-thalassemias and hemoglobinopathies are serious genetic blood diseases, which are who-designated as a… $1,843,809 $1,843,809
Amendment $0 $0
Original award $1,733,012 $0

Quick answers

Who received award R33HL147845?

R33HL147845 was awarded to Phoenicia Biosciences, Inc. by National Heart Lung and Blood Institute (National Institutes of Health) on June 1, 2020.

How much is award R33HL147845 worth?

$12,368,252 has been obligated on R33HL147845: $10,524,443 in federal funding and $1,843,809 in non-federal funding.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award
Try for free Login